aPROMISE
aPROMISE is intended to be used by healthcare professionals and researchers for acceptance, transfer, storage, image display, manipulation, quantification, and reporting of digital medical images acquired on nuclear medicine studies, specifically PSMA/CT exams.1
- Prostate
- PSMA
- PET/CT
- PACS
The Prevalence of Prostate Cancer2
About one in eight men will be diagnosed with prostate cancer during their lifetime. Prostate cancer is the most common cancer in American men and the second leading cause of cancer deaths in men in the US. The Prostate cancer death rate declined by about half from 1993 to 2013, most likely due to earlier detection and advances in treatment in the US. In recent years, the death rate has stabilized, likely reflecting the rise in cancers being found at an advanced stage.
Support Nuclear Medicine1
The aPROMISE system is intended for use with images acquired using PSMA PET/CT nuclear medical imaging. The device provides general PACS tools. In addition it has a clinical application for oncology with marking of regions of interest and quantitative analysis.
Greater consistency, compared to manually generated values.3
Consistency. Efficiency.
Diagnostic Accuracy.
Enhances the reproducibility and reliability among readers.1
91.5% sensitivity of regional lymph node detection, 86.7% for bone in metastatic patients.1
Enables detection and volumetric quantification of disease burden in PSMA PET/CT images.4,5
1EXINI. ePROMISE. EU User Guide PRA3152-v.15. Accessed July 2023.
2American Cancer Society. Key Statistics for Prostate Cancer. Accessed July 2023.
3 Johnsson K, Brynolfsson J, Sahlstedt H, et al. Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting. Eur J Nucl Med Mol Imaging. 2022;49(3):1041-1051. doi:10.1007/s00259-021-05497-8
4 Nickols N, Anand A, Johnsson K, et al. aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in 18F-DCFPyL Images of Veterans with Prostate Cancer. J Nucl Med. 2022;63(2):233-239. doi:10.2967/jnumed.120.261863
5 aPROMISE IFU
Currently not available within the Calantic Viewer.
